Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

PolyTherics Limited, a provider of solutions to enable the development of better biopharmaceuticals, and Spirogen Limited, a leading oncology-focused company developing DNA sequence-targeted agents, announce that they have formed a research collaboration to develop antibody drug conjugates that combine PolyTherics' proprietary site-specific conjugation chemistry with Spirogen's highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer.

2 Apr 2012

MabCure retains CUNY CAT to evaluate monoclonal antibodies against ovarian cancer

MabCure Inc., a leading developer of antibody-based technology for the diagnosis and treatment of ovarian, prostate, colorectal and other cancers, has retained the CUNY Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

29 Mar 2012

Potential new therapy that kills cancer cells selectively

Researchers have made a drug that helps the immune system to break down cancerous tumors. It has worked on breast, bowel, prostate, ovarian, brain, bladder and liver cancers, while previous studies show it can also be used to fight some blood cancers. If given early, the drug could even be a cure, researchers say.

28 Mar 2012

Olaparib improves survival rates in platinum-sensitive relapsed serous ovarian cancer

Today at the Society of Gynecologic Oncology (SGO) 43rd Annual Meeting on Women's Cancer®, Dr. Jonathan Ledermann, Director of Cancer Services and Professor of Medical Oncology at University College London, presented new data updating the overall survival of women enrolled in a "Phase II randomized placebo-controlled study of olaparib (AZD2281) maintenance in patients with platinum-sensitive relapsed serous ovarian cancer."

28 Mar 2012

NY-ESO-1 vaccine shows promise against ovarian cancer, melanoma

An immunotherapy regimen incorporating poxviruses and targeting a particular tumor antigen, NY-ESO-1, has shown promise in treating two types of cancers.

27 Mar 2012

Vermillion fourth quarter total revenues increase 152% to $868,000

Vermillion, Inc., a leading molecular diagnostics company, reported financial and operational results for the fourth quarter and full year ended December 31, 2011.

From Quest Diagnostics 27 Mar 2012

Testosterone receptor may be a potential target for triple negative breast cancer

Could blocking a testosterone receptor lead to a new way to treat an aggressive form of breast cancer? That's a question researchers at Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) are exploring. Preliminary results of a Mayo Clinic - TGen collaborative study shows the testosterone receptor may be a potential target to attack in treating triple negative breast cancer (TNBC).

26 Mar 2012

Testosterone may play a role in treatment of triple negative breast cancer

23 Mar 2012

Genetic marker identifies tumors unable to repair DNA damage by platinum agents

Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.

23 Mar 2012

tAI could predict sensitivity to chemotherapy in patients with triple-negative breast cancer

Scientists have uncovered a marker of DNA damage that could predict who will respond to platinum-based chemotherapy drugs like cisplatin or carboplatin.

23 Mar 2012

MabCure, CUNY CAT partner to evaluate monoclonal antibodies against ovarian cancer cells

MabCure Inc., leading developer of antibody based technology for the diagnosis and treatment of Ovarian, Prostate, Colorectal and other cancers today announced it has entered into an agreement with the City University of New York Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

19 Mar 2012

Specialised cancer centers may improve survival rates for patients

Survival rates for cancer patients may be improved by treatment in specialised cancer centers, according to Cochrane researchers. In a review of recent studies, they found that women diagnosed with gynaecological cancer lived longer when treated in specialist compared to non-specialist units.

15 Mar 2012

Ovarian cancer – push for greater awareness

Women are being warned about ovarian cancer – mostly a silent killer, since many do not know what symptoms to look out for. Each year in the UK around 6,700 women are diagnosed with the disease and more than 4,000 women lose their lives.

12 Mar 2012

Illumina launches new highly multiplexed cancer panel

Illumina today introduced the TruSeq Amplicon - Cancer Panel, a highly multiplexed panel that will allow researchers to accurately sequence hundreds of the most relevant cancer loci, even in difficult samples such as formalin-fixed, paraffin embedded (FFPE) tumor samples.

From Illumina, Inc. 7 Mar 2012

Novel set of genes linked with epithelial ovarian cancer patient survival

Researchers at Moffitt Cancer Center and colleagues from 11 other institutions in the United States and the United Kingdom have used two genome-wide association studies (GWAS) - one from the U.S. and one from the U.K. - to detect a novel set of genes found to be associated with epithelial ovarian cancer patient survival.

7 Mar 2012

Penn-led team develops universal approach to personalized cancer therapy based on T cells

Researchers from the Perelman School of Medicine at the University of Pennsylvania report this month in Cancer Research a universal approach to personalized cancer therapy based on T cells. It is the first time a system for making an adaptable, engineered T-cell to attack specific tumor types has been proposed, depending on which abnormal proteins, called antigens, are expressed by individual patients' tumor cells.

6 Mar 2012

EntreMed plans to establish drug development office in China

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has initiated plans to establish an office in China to facilitate the Company's drug development and clinical trials in that country.

6 Mar 2012

Access full year 2011 revenues increase 284%

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and cancer supportive care,announced preliminary revenue results for fourth quarter 2011 and full year 2011. Fourth quarter MuGard product sales increased 400% over third quarter product sales.

5 Mar 2012

Viewpoints: The defeated Blunt Amendment, Obama's $100B Catholic hospital risk, fixing drug shortages

The amendment, which was attached to a highway bill, was defeated on a narrow 48-to-51 vote. But it showed once again how far from the mainstream Republicans have strayed in their relentless efforts to undermine the separation of church and state, deny women access to essential health services and tear apart President Obama's health care reform law.

3 Mar 2012

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2011, and provided an update on the Company's key business initiatives.

29 Feb 2012

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

MabCure retains CUNY CAT to evaluate monoclonal antibodies against ovarian cancer

Potential new therapy that kills cancer cells selectively

Olaparib improves survival rates in platinum-sensitive relapsed serous ovarian cancer

NY-ESO-1 vaccine shows promise against ovarian cancer, melanoma

Vermillion fourth quarter total revenues increase 152% to $868,000

Testosterone receptor may be a potential target for triple negative breast cancer

Testosterone may play a role in treatment of triple negative breast cancer

Genetic marker identifies tumors unable to repair DNA damage by platinum agents

tAI could predict sensitivity to chemotherapy in patients with triple-negative breast cancer

MabCure, CUNY CAT partner to evaluate monoclonal antibodies against ovarian cancer cells

Specialised cancer centers may improve survival rates for patients

Ovarian cancer – push for greater awareness

Illumina launches new highly multiplexed cancer panel

Novel set of genes linked with epithelial ovarian cancer patient survival

Penn-led team develops universal approach to personalized cancer therapy based on T cells

EntreMed plans to establish drug development office in China

Access full year 2011 revenues increase 284%

Viewpoints: The defeated Blunt Amendment, Obama's $100B Catholic hospital risk, fixing drug shortages

EpiCept fourth quarter revenue decreases to $0.2 million

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in